Sangamo Therapeutics (SGMOQ) Interest & Investment Income (2011 - 2025)
Sangamo Therapeutics (SGMOQ) posted Interest & Investment Income of $252000.0 for Q4 2025, down 29.01% on a QoQ basis from $355000.0 in Q3 2025, and down 14.86% year-over-year from $296000.0 in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Interest & Investment Income (2011 - 2025) Analysis & Trends
Sangamo Therapeutics has reported Interest & Investment Income for 15 years, with the latest figure at $252000.0 in Q4 2025.
- On a quarterly basis, Interest & Investment Income fell 14.86% year-over-year to $252000.0 in Q4 2025; TTM through Dec 2025 was $1.3 million, a 13.95% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 13.95% from the prior year.
- Interest & Investment Income was $252000.0 for Q4 2025 at Sangamo Therapeutics, down from $355000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $3.7 million in Q4 2022, with the low at $252000.0 in Q4 2025.
- Average Interest & Investment Income over 5 years is $1.4 million, with a median of $1.1 million recorded in 2021.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income surged 145.38% in 2023, then plunged 90.04% in 2024.
- Over 5 years, Interest & Investment Income stood at $2.3 million in 2021, then soared by 57.45% to $3.7 million in 2022, then tumbled by 59.43% to $1.5 million in 2023, then plunged by 80.16% to $296000.0 in 2024, then slipped by 14.86% to $252000.0 in 2025.
- The last three Interest & Investment Income figures came in at $252000.0 (Q4 2025), $355000.0 (Q3 2025), and $386000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.09 Bn | 9.24 Bn | 112.79 Mn | 7.66 Mn |
| 2 | CRISPR Therapeutics AG | 5.22 Bn | 5.22 Bn | - | -2.69 Mn |
| 3 | Iovance Biotherapeutics | 3.90 Bn | 3.60 Bn | 55.72 Mn | 3.22 Mn |
| 4 | Legend Biotech | 3.67 Bn | 2.70 Bn | 251.50 Mn | 5.60 Mn |
| 5 | uniQure | 3.10 Bn | 3.10 Bn | 5.49 Mn | 5.05 Mn |
| 6 | Beam Therapeutics | 2.69 Bn | 2.69 Bn | - | 7.49 Mn |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | 366,000.00 |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.82 Bn | 56.40 Mn | 1.95 Mn |
| 10 | Sangamo Therapeutics | 43.29 Mn | 22.34 Mn | - | 252,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 252,000.00 |
| Sep 30, 2025 | 355,000.00 |
| Jun 30, 2025 | 386,000.00 |
| Mar 31, 2025 | 309,000.00 |
| Dec 31, 2024 | 296,000.00 |
| Sep 30, 2024 | 350,000.00 |
| Jun 30, 2024 | 416,000.00 |
| Mar 31, 2024 | 451,000.00 |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | 3.52 Mn |
| Jun 30, 2023 | 2.80 Mn |
| Mar 31, 2023 | 3.29 Mn |
| Dec 31, 2022 | 3.68 Mn |
| Sep 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 2.64 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 2.34 Mn |
| Sep 30, 2021 | 834,000.00 |
| Jun 30, 2021 | 1.55 Mn |
| Mar 31, 2021 | 625,000.00 |